Biocitech companies experienced positive growth in 2014 as the arrival of seven new companies led to a 25% increase in on-site residents
Romainville, France, April 29, 2015 – Biocitech, the city complex for healthcare and biotechnology companies based at the edge of Paris, today announces the 2014 results achieved by its residents.
Positive economic trends for residents
Biocitech residents submitted encouraging results for 2014, with growth in many areas. The overall revenue for the complex’s residents grew by 21%, from €51.3 million ($55.5 million) in 2013 to €62 million ($67 million) in 2014. Some companies, such as Actolis, Adebiotech, Metabolium, Pharma Biot’Expert and PrimaDiag, saw revenue boosts ranging from 50% to nearly 300%. Other residents maintained a steady level of revenue and made large investments in research and development
The revenue boost for Biocitech residents is largely due to a 12% increase in external clients, with the number of client contracts increasing by 80%. Other figures, such as staff numbers, preclinical and clinical studies, the number of contracts signed and the number of partnerships between residents and foreign companies, have remained stable. These results stem from both the efforts of the residents and the quality of the Biocitech ecosystem. Biocitech provides a nurturing environment where companies can grow with support from a network of external partners. This network includes the CCI (Chamber of Commerce and Industry), AP-HP (The Paris network of teaching hospitals) and competitive clusters such as Medicen Paris Region, Cap Digital and Systematic.
Biocitech residents are optimistic in their forecasts for 2015, with the majority having a positive view on both the past year and the year ahead. This positive attitude reflects the improving economic situation and morale of French entrepreneurs. Other promising signs for the residents include developing prospects, the diversification of activities and partnerships formed with foreign companies.
Despite the promising outlook, financing of the residents’ activities remains demanding. In 2014 many residents had to rely on subsidies and grants that did not meet their financial needs. Most companies do not have sufficient funds of their own, making it difficult for them to obtain subsidies. The overwhelming majority rely on R&D tax credits (CIR for Crédit Impot Recherche) to finance activities. However some residents did manage to raise significant funds; Pherecydes Pharma raised €1.9 million ($2 million) in order to continue its development plan, while PrimaDiag successfully raised €212,000 ($229,000) through crowdfunding. Many other residents are considering turning to this as a means of alternative funding in 2015.
“We are very satisfied with the positive growth experienced by many residents in the Biocitech complex,” said Jean-François Boussard, CEO of Biocitech. “The increased revenue of our residents and the arrival of seven new residents in 2014 show that we are making the right strategic choices. We redesigned Biocitech to create a city complex that is open to biotechnology and healthcare companies from inception to business maturity. On January 31, 2014 we celebrated our ten-year anniversary. Over the past decade we have supported many innovative startups that continue to grow thanks to the benefits offered by the city complex. Our residents are at the very heart of innovative sectors, experiencing growth and looking to the future. We will continue to support their efforts in 2015.”
Objectives for 2015
Encouraged by these promising results, Biocitech plans to complete its ambitious five-part development program in 2015:
• Refurbish the Galien building • Renovate the auditorium • Restore the rainwater reservoir • Construct a new building for facility management • Modernize utilities: energy supplies (heat, cold, nitrogen, vacuum energy, compressed air, deionized water), install fiber optic cables, etc.
By overhauling aspects of the rental space and upgrading equipment to support current technological trends, the goal is to ensure that the city complex remains an attractive base for the development of biotechnology and healthcare companies.
Biocitech will also continue to organize numerous national and international scientific events and business forums to encourage collaboration between residents and external stakeholders. Internal collaboration is equally important; companies should share ideas and skills in order to make their activities even more dynamic. Biocitech aims to provide residents with all the tools they need to continue their development.
About BIOCITECH
BIOCITECH is a city complex for healthcare and biotechnology companies. Located at the edge of Paris, BIOCITECH fosters business innovation and growth (plug&grow) and provides a complete range of services to residents from inception through to business maturity (plug&live).
BIOCITECH’s package includes real estate services, scientific services, technical services and communal services that support entrepreneurial development. BIOCITECH is ICPE certified (Equipment Certified to Protect the Environment) and provides entrepreneurs with secure premises of a high technological standard.
BIOCITECH generates strong synergies and numerous collaborations for resident firms that are at the forefront of innovation. BIOCITECH is a key element in the Medicen Paris region’s world-class competitiveness hub for health and new therapies and also belongs to the Cap Digital and Systematic clusters.
Help employers find you! Check out all the jobs and post your resume.
Romainville, France, April 29, 2015 – Biocitech, the city complex for healthcare and biotechnology companies based at the edge of Paris, today announces the 2014 results achieved by its residents.
Positive economic trends for residents
Biocitech residents submitted encouraging results for 2014, with growth in many areas. The overall revenue for the complex’s residents grew by 21%, from €51.3 million ($55.5 million) in 2013 to €62 million ($67 million) in 2014. Some companies, such as Actolis, Adebiotech, Metabolium, Pharma Biot’Expert and PrimaDiag, saw revenue boosts ranging from 50% to nearly 300%. Other residents maintained a steady level of revenue and made large investments in research and development
The revenue boost for Biocitech residents is largely due to a 12% increase in external clients, with the number of client contracts increasing by 80%. Other figures, such as staff numbers, preclinical and clinical studies, the number of contracts signed and the number of partnerships between residents and foreign companies, have remained stable. These results stem from both the efforts of the residents and the quality of the Biocitech ecosystem. Biocitech provides a nurturing environment where companies can grow with support from a network of external partners. This network includes the CCI (Chamber of Commerce and Industry), AP-HP (The Paris network of teaching hospitals) and competitive clusters such as Medicen Paris Region, Cap Digital and Systematic.
Biocitech residents are optimistic in their forecasts for 2015, with the majority having a positive view on both the past year and the year ahead. This positive attitude reflects the improving economic situation and morale of French entrepreneurs. Other promising signs for the residents include developing prospects, the diversification of activities and partnerships formed with foreign companies.
Despite the promising outlook, financing of the residents’ activities remains demanding. In 2014 many residents had to rely on subsidies and grants that did not meet their financial needs. Most companies do not have sufficient funds of their own, making it difficult for them to obtain subsidies. The overwhelming majority rely on R&D tax credits (CIR for Crédit Impot Recherche) to finance activities. However some residents did manage to raise significant funds; Pherecydes Pharma raised €1.9 million ($2 million) in order to continue its development plan, while PrimaDiag successfully raised €212,000 ($229,000) through crowdfunding. Many other residents are considering turning to this as a means of alternative funding in 2015.
“We are very satisfied with the positive growth experienced by many residents in the Biocitech complex,” said Jean-François Boussard, CEO of Biocitech. “The increased revenue of our residents and the arrival of seven new residents in 2014 show that we are making the right strategic choices. We redesigned Biocitech to create a city complex that is open to biotechnology and healthcare companies from inception to business maturity. On January 31, 2014 we celebrated our ten-year anniversary. Over the past decade we have supported many innovative startups that continue to grow thanks to the benefits offered by the city complex. Our residents are at the very heart of innovative sectors, experiencing growth and looking to the future. We will continue to support their efforts in 2015.”
Objectives for 2015
Encouraged by these promising results, Biocitech plans to complete its ambitious five-part development program in 2015:
• Refurbish the Galien building • Renovate the auditorium • Restore the rainwater reservoir • Construct a new building for facility management • Modernize utilities: energy supplies (heat, cold, nitrogen, vacuum energy, compressed air, deionized water), install fiber optic cables, etc.
By overhauling aspects of the rental space and upgrading equipment to support current technological trends, the goal is to ensure that the city complex remains an attractive base for the development of biotechnology and healthcare companies.
Biocitech will also continue to organize numerous national and international scientific events and business forums to encourage collaboration between residents and external stakeholders. Internal collaboration is equally important; companies should share ideas and skills in order to make their activities even more dynamic. Biocitech aims to provide residents with all the tools they need to continue their development.
About BIOCITECH
BIOCITECH is a city complex for healthcare and biotechnology companies. Located at the edge of Paris, BIOCITECH fosters business innovation and growth (plug&grow) and provides a complete range of services to residents from inception through to business maturity (plug&live).
BIOCITECH’s package includes real estate services, scientific services, technical services and communal services that support entrepreneurial development. BIOCITECH is ICPE certified (Equipment Certified to Protect the Environment) and provides entrepreneurs with secure premises of a high technological standard.
BIOCITECH generates strong synergies and numerous collaborations for resident firms that are at the forefront of innovation. BIOCITECH is a key element in the Medicen Paris region’s world-class competitiveness hub for health and new therapies and also belongs to the Cap Digital and Systematic clusters.
Help employers find you! Check out all the jobs and post your resume.
